FDA Approval for New Abbott Labs (ABT) MitraClip Indication 'Triples' U.S. Patient Population - Cowen
Tweet Send to a Friend
Cowen analyst Joshua Jennings reiterated an Outperform rating and $86.00 price target on Abbott Labs (NYSE: ABT) after the FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
